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SObjective: The prognosis of patients with idiopathic pulmonary fibrosis or fibrosing idiopathic nonspecific
interstitial pneumonia undergoing invasive mechanical ventilation (MV) for acute respiratory failure is known
to be poor. The issue of life support in these patients needs to be reconsidered in light of changes during the past
decade in ventilator settings and in the management of acute exacerbation. We therefore aimed to reassess the
prognosis of such patients.
Methods:We retrospectively assessed the outcomes of all medical patients with idiopathic pulmonary fibrosis
or fibrosing idiopathic nonspecific interstitial pneumonia who required invasive MV in 3 university hospitals in
the Paris area from January 2002 to April 2009.
Results: In total, 27 patients (mean age, 66  12.8 years) required invasive MV in the intensive care unit:
8 (30%) were successfully weaned from MV, and 6 and 4 were discharged from the intensive care unit and
the hospital, respectively. Survivals for patients who did not undergo lung transplant were 22%, 3.7%, and
3.7%, at 30 days, 6 months, and 12 months, respectively.
Conclusions: We confirm that use of invasive MV for acute respiratory failure in patients with idiopathic
pulmonary fibrosis or fibrosing idiopathic nonspecific interstitial pneumonia is associated with a high mortality;
however, a subset of patients may be discharged alive from the intensive care unit and hospital, providing an
opportunity to consider lung transplant in case of eligibility. Our results suggest that invasive MV should not
be systematically denied to these patients but discussed on a case-by-case basis. (J Thorac Cardiovasc Surg
2014;147:47-53)The prognosis is poor for the most common idiopathic
fibrosing interstitial pneumonias, idiopathic pulmonary
fibrosis (IPF) and idiopathic nonspecific interstitial
pneumonia (iNSIP) in its fibrotic form. In particular, the
median survival after diagnosis of IPF is 2 to 3 years.1
The clinical courses of IPF and iNSIP are usually slowly
progressive but may be complicated by episodes of acute
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The Journal of Thoracic and C(ARF), the patient’s condition may worsen despite symp-
tomatic treatment, possible leading to referral to an
intensive care unit (ICU) and the requirement of invasive
mechanical ventilation (MV). Guidelines concerning the
referral to the ICU and initiation of MV are lacking;
however, the literature suggests that invasive MV for
patients with IPF is appropriate when respiratory failure
follows a surgical procedure but is questionable for medical
patients because the short- or medium-term outcome is
poor, according to several convergent studies.2-7 This has
led many intensivists to deny initiation of invasive MV in
this setting8; however, most studies investigating outcomes
after MV in fibrotic lung diseases involved patients who
underwent MV back in the 1990s.
We aimed to reassess the prognosis of medical patients
with idiopathic fibrosing interstitial pneumonias (IPF and
iNSIP) who required invasive MV in the ICU. Our
hypothesis was that the prognosis of these patients might
have improved with time, at least with respect to the
short-term (ICU) mortality because of developments in
the past decade in ventilator settings and management of
acute exacerbation in patients undergoing MV, as suggested
in a recently published letter.9 This question seems relevant
because an improvement in even short-term prognosis couldardiovascular Surgery c Volume 147, Number 1 47
Abbreviations and Acronyms
ARF ¼ acute respiratory failure
BAL ¼ bronchoalveolar lavage
ECMO ¼ extracorporeal membrane oxygenation
ICU ¼ intensive care unit
IPF ¼ idiopathic pulmonary fibrosis
iNSIP ¼ idiopathic nonspecific interstitial
pneumonia
LTx ¼ lung transplant
MV ¼ mechanical ventilation
VT ¼ tidal volume
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Sallow access to lung transplant (LTx) for patients who are
eligible for this procedure.10 We conducted a retrospective
study of patients with IPF in the ICUs of 3 university
hospitals. We also investigated patients with fibrosing
iNSIP because of their similarities in terms of clinical
decision making at the time of admission to an ICU.
MATERIALS AND METHODS
This was a retrospective study of patients in 3 ICUs of teaching hospitals
in the Paris area, particularly hospitals involved in care of interstitial
pulmonary diseases (Bichat Hospital, Avicenne Hospital, Ho^tel Dieu
Hospital). We analyzed the medical charts of all patients with fibrosing
idiopathic interstitial pneumonia (IPF or fibrosing iNSIP) who required
invasive MV from January 2002 to April 2009. This study was approved
by the ethics committee of the Societe de Reanimation de Langue
Franc¸aise (project 08-263, June 18, 2009).
The diagnosis of IPF was based on histologic evaluation (surgical lung
biopsy, transbronchial biopsy, or autopsy) indicative of usual interstitial
pneumonia and the absence of an identifiable cause (professional exposure,
drug toxicity, identified connective tissue disease). In the absence of
histologic evaluation, patients had to fulfill all major criteria and at least 3 of
the 4 minor criteria of the American Thoracic Society (ATS) and European
Thoracic Society.11 Diagnosis of fibrosing iNSIP was based on a histologic
evaluation indicative of a fibrotic pattern of nonspecific interstitial pneumonia
in the absence of an identifiable cause (drug toxicity, infection, connective
tissue disease) as proposed by the consensus conference of the American
Thoracic Society and European Respiratory Society published in 2002.1
Invasive MV was defined as the use of MV through an endotracheal tube
(orotracheal, nasotracheal intubation, or tracheostomy). All selected patients
had undergone invasive MV for ARF or hemodynamic failure. Patients with
MV who were admitted to the ICU for simple monitoring after a surgical
procedure or a bronchoscopy were excluded.
Data Gathering
We recorded data from medical charts.
Characteristics of patients at baseline. Baseline data included
age, sex, body mass index, smoking habit, comorbidities (ischemic heart
disease, systemic hypertension, and diabetes), diagnosis (IPF or fibrosing
iNSIP), type of histologic evidence if available, disease duration, results
from most recent pulmonary function tests (including vital capacity, total
lung capacity, ratio of forced expiratory volume in 1 second to vital
capacity, carbon monoxide diffusing capacity), blood gas analysis,
pulmonary hypertension at baseline (defined as mean pulmonary arterial
pressure>25 mm Hg at the right heart catheterization or arbitrarily as
systolic pulmonary arterial pressure>50 mm Hg when measured by echo-
cardiography at rest12), requirement of long-term oxygen therapy, use of48 The Journal of Thoracic and Cardiovascular Surgecorticosteroids or immunosuppressive therapy at the time of admission,
curative anticoagulation therapy, and registration on a waiting list for LTx.
Characteristics on admission to the ICU. ICU admission
data included Simplified Acute Physiology Score II, Acute Physiology
and Chronic Health Evaluation II score, and reason for ICU admission.
Management in the ICU. ICU management data included time
elapsed between admission and the beginning of invasiveMV, use of nonin-
vasive ventilation before intubation, ventilator settings after intubation
(ventilation mode, tidal volume [VT] expressed in mL/kg ideal body
weight, level of positive end-expiratory pressure, plateau pressure), need
for systemic catecholamines within 24 hours after intubation, best PaO2/
fraction of inspired oxygen ratio and best PaCO2 within 24 hours after intu-
bation, type of microbiologic respiratory sampling if available obtained
before or soon after intubation (bronchoalveolar lavage [BAL], protected
distal sampling, tracheal aspirate), type of antibiotics received after admis-
sion in the ICU, use of high-dose intravenous ‘‘pulse’’ methylprednisolone,
introduction of immunosuppressive drugs, use of curative anticoagulation
therapy, treatment with N-acetylcysteine, use of inhaled nitric oxide after
intubation, requirement of extracorporeal membrane oxygenation
(ECMO) at any time during the ICU stay, weaning from MV, performance
of LTx during the ICU stay, and discharge from versus death in the ICU.
Characteristics after the ICU stay. Data collected after the ICU
stay included discharge from the hospital versus death in the hospital and
LTx.
Survival. Survivals were determined at 30 days, 6 months, and
12 months after ICU admission.
Data Review
Clinical, biologic, and radiologic data were reviewed retrospectively by
2 investigators (S.G. and H.M.) to determine the cause of admission to the
ICU. The diagnosis of bacterial pneumonia was based on radiographic
evidence of new infiltrates and significant concentration of bacteria in
respiratory specimens (>104 colony-forming units/mL on BAL, >103
colony-forming units/mL on protected distal sampling, >106 colony-
forming units/mL on tracheal aspirate). Diagnosis of Pneumocystis
pneumonia was based on the presence of Pneumocystis jirovecii in BAL
fluid. Diagnosis of acute exacerbation of IPF was based on criteria defined
by Collard and colleagues13: (1) onset or recent increase of dyspnea
(<30 days), (2) appearance of ground-glass opacities or superimposed
condensation on preexisting reticular opacities and honeycombing, (3)
absence of infectious precipitating factor, and (4) absence of another
identifiable cause (eg, heart failure, pulmonary embolism, pneumothorax).
Successful weaning from MV was defined as extubation or ability to
breathe spontaneously for 24 hours on tracheostomy cannula. ICU survival
and hospital survival were defined as discharge of the patient from the ICU
and hospital, respectively.
Statistical Analysis
Statistical analysis involved use of GraphPad Prism 5 (GraphPad
Software, San Diego, Calif). Categoric data are described by number and
percentage and were compared by c2 test. The distribution of continuous
data was tested by the Kolmogorov-Smirnov test. Continuous data with
normal distribution are described by mean  SD and were compared
with the Student t test. Continuous data with nonnormal distribution are
described by median with interquartile range (25%-75%) and were
compared with the Mann-Whitney U test. The Kaplan-Meier estimator
was used to estimate survival.RESULTS
Baseline Characteristics of Patients
Baseline patient characteristics were determined by
analysis of charts for 27 patients (23 men; mean age,ry c January 2014
TABLE 2. Management of patients in intensive care unit
Tidal volume (mL/kg predicted body weight) 5.9  1.3
PEEP (cm H2O) 7.1  3.3
Inhaled nitric oxide (No.) 9 (33%)
Plateau pressure (cm H2O, n ¼ 14) 33.4  7.3
Respiratory samples (No.) 27 (100%)
Bronchoalveolar lavage 17
Protected distal sampling 8
Tracheal aspiration 2
Steroid pulse (No.) 13 (48%)
Cyclophosphamide (No.) 2 (7%)
Empirical antibiotic therapy (No.) 24 (89%)
Effective anticoagulation (No.) 12 (44%)
Before ICU admission 4
During ICU stay 8
For acute exacerbation 7
For pulmonary embolism 1
N-acetylcysteine (No.) 4 (15%)
ECMO (No.) 2 (7%)
Data are mean  SD unless indicated. PEEP, Positive end-expiratory pressure;
ICU, intensive care unit; ECMO, extracorporeal membrane oxygenation.
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S66.6  12.8 years) (Table 1). Among these patients, his-
tories included smoking (past or active) in 17 cases
(63%), diabetes in 6 (22%), ischemic heart disease in 5
(19%), and systemic hypertension in 9 (33%). At the
time of admission, all patients already had an established
diagnosis of IPF or fibrosing iNSIP. Histologic evidence
was available for 10 patients (37%; surgical biopsies,
n ¼ 7; postmortem examination, n ¼ 2; transbronchial
biopsy, n ¼ 1). Overall, 22 patients (81.5%) had IPF and
5 (18.5%) had fibrosing iNSIP. The median delay between
symptom onset and admission to the ICU was 1.9 years
(interquartile range, 1.1-3.8 years).
Pulmonary function tests performed at baseline showed a
restrictive syndrome in all patients, with mean total lung
capacity 50.7% 13.6% predicted and mean vital capacity
53.3%  15.4% predicted. Mean carbon monoxide
diffusing capacity was 29.7%  12.8% predicted. In total,
7 patients (26%) had pulmonary hypertension, 15 (55%)
were receiving long-term oxygen therapy, 2 were on a
waiting list for LTx, 17 (63%) were receiving long-term
corticosteroids, 9 (33%) were receiving immunosuppres-
sive therapy combined with corticosteroids (azathioprine,
n ¼ 5; cyclophosphamide, n ¼ 2; mycophenolate mofetil,
n ¼ 2), and 4 (15%) had curative anticoagulation before
hospitalization.Characteristics and Management in the ICU
ICU characteristics and management were determined
for all 27 patients (Table 2). All were admitted to an ICU
for ARF. Mean Simplified Acute Physiology Score II andTABLE 1. Characteristics of patients
Age (y) 66.6  12.8
Male sex (No.) 23 (85%)
Body mass index (kg/m2) 26.1  4.7
IPF/iNSIP case ratio 22/5
Histologic confirmation of diagnosis (No.) 10 (37%)
Duration of disease progression (y, median and IQR) 1.9 (1.1-3.8)
Long-term oxygen therapy (No.) 15 (55%)
Pulmonary arterial hypertension (No.) 7 (26%)
PaCO2 baseline (mm Hg) 41  6.4
Total lung capacity (% predicted) 50.7%  13.6%
VC (% predicted) 53.3%  15.4%
FEV1/VC (%) 84.3%  9.7%
DLCO (% predicted) 29.7%  12.8%
DLCO/VA (% predicted) 68.9%  21.5%
On waiting list for transplant (No.) 2 (7%)
Long-term corticosteroid treatment (No.) 17 (63%)
Immunosuppressive therapy (No.) 9 (33%)
Curative anticoagulation (No.) 4 (15%)
History of previous acute exacerbation (No.) 5 (19%)
Data are mean  SD unless indicated. IPF, Idiopathic pulmonary fibrosis;
iNSIP, idiopathic nonspecific interstitial pneumonia; IQR, interquartile range;
VC, vital capacity; FEV1, forced expiratory volume in 1 second; DLCO, carbon
monoxide diffusing capacity; VA, alveolar volume.
The Journal of Thoracic and Cmean Acute Physiology and Chronic Health Evaluation II
scores were 47  24 and 22  11, respectively, for the
whole cohort. In total, 17 patients (63%) were intubated
within the first 24 hours and 19 (70%) underwent noninva-
sive ventilation sessions before intubation. On the day of
intubation, 19 patients (70%) had hemodynamic failure
requiring intravenous catecholamines. Most patients, 22
(81%), underwent contrast-enhanced computed tomogra-
phy of the thorax during hospitalization. In the early days
of the ICU stay, all patients underwent respiratory sampling
to search for an infectious cause (BAL, n ¼ 17; protected
distal sampling, n ¼ 8; tracheal aspiration, n ¼ 2).
The cause of ARF was identified in 24 patients (89%):
acute exacerbation of fibrosis (n ¼ 14, 52%), lower
respiratory tract infection (n ¼ 5, 19%), pulmonary
embolism (n ¼ 1), septic shock (n ¼ 2, pyelonephritis
and acute infectious colitis n ¼ 1 each), bronchioloalveolar
carcinoma (n ¼ 1), and hemorrhagic shock (n ¼ 1).
Among the 5 respiratory tract infections, 4 were bacterial
(Pseudomonas aeruginosa, n ¼ 2; Streptococcus pneumo-
niae, n ¼ 1; Staphylococcus aureus, n ¼ 1) and 1 fungal
(pneumocystosis).
After intubation, all patients were sedated and receiving
volume assist-control ventilation (mean, VT 5.9  1.3
mL/kg; mean positive end-expiratory pressure, 7.1  3.3
cm H2O). The corresponding mean plateau pressure at
day 0 was 33.4  7.3 cm H2O (data available for 14 pa-
tients). Blood gas analysis performed within 6 hours after
the initiation of invasive MV showed profound hypoxemia
(mean PaO2/fraction of inspired oxygen ratio, 135  72)
and hypercapnia (mean PaCO2, 60  18 mm Hg). In total,
9 patients (33%) received inhaled nitric oxide during the
period of invasive MV. Two patients required ECMO whileardiovascular Surgery c Volume 147, Number 1 49
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Swaiting for LTx. Before the results of microbiologic
sampling, 24 patients (89%) received empirical antibiotic
therapy (most often broad-spectrum antibiotic therapy).
Among 14 patients with acute exacerbation of fibrosis, 13
received high-dose intravenous ‘‘pulse’’ methylpredniso-
lone in the ICU. In addition, 2 patients received intravenous
cyclophosphamide. Among the 23 patients who were not
receiving curative anticoagulation before hospitalization
in the ICU, 8 received curative unfractionated heparin
(7 because of acute exacerbation of fibrosis and 1 because
of pulmonary embolism).
During the ICU stay, ventilator-acquired pneumonia
developed in 3 patients, and 2 had pneumothorax.Outcomes
Outcomes are shown in Figure 1. Of the 27 patients, 20
died in the ICU, including 1 undergoing ECMO. The causes
of death were as follows: refractory hypoxemia (n ¼ 13),
multiorgan failure related to sepsis (n ¼ 6), and intracere-
bral hemorrhage (in the patient undergoing ECMO). One
patient underwent LTx during ECMO. In total, 8 patients
(30%) were successfully weaned from invasive MV, 1 after
undergoing tracheostomy for weaning purposes. Of these 8
patients, 2 subsequently died while in the ICU and 6 (22%)
were discharged from the ICU (5 with IPF and 1 with
fibrosing iNSIP).
The median duration of invasive MV in the 6 patients
discharged alive from the ICU was 5.5 days (interquartile
range 3.5-14.7). The causes of ARF in these 6 patients
were lower respiratory tract infection (n ¼ 3), acute
exacerbation of fibrosis (n ¼ 2), and unidentified (n ¼ 1).Fibrosing idiopathic 
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FIGURE 1. Outcomes of patients with fibrosing idiopathic interstiti
50 The Journal of Thoracic and Cardiovascular SurgeTwo patients died in the general hospital ward after
discharge from the ICU (cardiac arrest n ¼ 1, new episode
of ARF related to the evolution of fibrosis n¼ 1), and 4 were
discharged alive from the hospital. Two of these 4
underwent LTx after their respiratory condition improved
after pulmonary rehabilitation, 1 died within 6 months after
hospital discharge because of evolution of pulmonary
fibrosis, and 1 was still alive 1 year after ICU admission.
Survivals for patients who did not undergo LTx were
22%, 3.7%, and 3.7% at 30 days, 6 months, and 12months,
respectively (Figure 2).DISCUSSION
We aimed to evaluate the prognosis of patients with
fibrosing idiopathic interstitial pneumonia who required
invasive MV for ARF in 3 Paris hospitals. Most patients
requiring invasive MV for acute deterioration of their
respiratory condition died while undergoing treatment in
the ICU. A subset of patients could be discharged alive
from the ICU; however, we found that their 6-month
mortality was high.
Several studies of medical patients have previously
analyzed the outcomes of patients with IPF admitted to an
ICU for respiratory failure.2-7 Most studies involved
patients who underwent MV in the 1990s. The results of
these studies, characterized by a retrospective design (like
ours) and small sample size (14 to 25 patients), were
convergent and showed a dismal prognosis. Except for
patients who underwent LTx, the mortality in the ICU
was 100% in almost all studies. In 1 study, 17% of
patients could be discharged from the ICU; however, halfinterstitial pneumonia, 
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FIGURE 2. Kaplan-Meier survival curve of patients with fibrosing
idiopathic interstitial pneumonia and invasive ventilation. Note that data
of the patient who underwent lung transplant before day 30 were censored
at the time of transplant.
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Sdied shortly thereafter.2 These results have led many
intensivists to consider that initiation of invasive MV is
futile in this setting and that only noninvasive ventilation
should be used.14
Our study of patients requiring invasive MV a decade
later yielded similar results in terms of overall prognosis;
however, we identified a subgroup of 6 patients (22%)
who could be discharged alive from the ICU, thus delaying
the date of death. These results cannot be explained by a
difference in terms of baseline severity of the disease,
because our patients’ characteristics (age, results of recent
pulmonary function tests, and requirement of long-term
oxygen therapy) are comparable to those in older series.
In line with our results, a recently published letter has
suggested that the prognosis of patients admitted to the
ICU for ARF and receivingMVmay have changed in recent
years. This study showed a better short-term prognosis
(30-day survival) for patients who received MV from
2005 to 2009 than for those treated from 1999 to 2004.
That study, however, mixed patients receiving noninvasive
and invasiveMVand did not describe the ventilator settings,
such as VT and plateau pressure.
Even if we are now able to provide a short-term survival
benefit for some patients, our data are in line with the
general perception that initiating MV for ARF in patients
with IPF is highly questionable, because most patients
died within 6 months. We believe, however, that the
situation is somewhat different if the patient can be
considered for LTx. Indeed, LTx is effective in improving
the survival of selected patients with IPF.15 In selected
patients who fulfill the criteria for LTx, invasive MV may
be used as a bridge to the procedure. The aim of invasive
MV would be to prevent immediate death from ARF and
to stabilize the cardiorespiratory condition for a time, thus
allowing the recipient to wait for an adequate organ.The Journal of Thoracic and CIn this setting, invasive MV may be used alone or in
association with ECMO. This bridging strategy, which is
being followed increasingly for selected patients with
lung fibrosis and ARF, is associated with a worse prognosis
than standard LTx,16-18 but it can provide a real chance of
survival for patients who would probably have died
otherwise.18,19 The most recent studies evaluating ECMO
as a bridge to LTx have yielded very encouraging
results.20,21 Moreover, the interesting option of
ambulatory ECMO could allow patient physical
rehabilitation before LTx.21,22 In the study by Hoopes and
colleagues,21 out of 31 patients who underwent ECMO as
a bridge to LTx, 19 were ambulatory at the time of LTx.
Another promising option that allows pretransplant
rehabilitation is ECMO in awake, nonintubated patients.23
The modification of allocation rules implemented in the
United States and Europe now allows performance of LTx
within several days or weeks in the most severe cases.18,19,24
The short-term survival benefit we observed with MV in
some patients, by delaying the date of death, could
potentially allow an increased probability of receiving a
lung for LTx. Only 1 patient in our series underwent
emergency LTx while undergoing invasive MV, which did
not influence our ICU survival results because that patient
was excluded from the survival analysis. LTx may also be
performed well after discharge from the ICU, as was the
case for 2 of our patients. Nevertheless, even if LTx can
be performed while the patient is undergoing MVor shortly
thereafter, it should ideally be performed earlier in the
course of the disease and the patients referred to a transplant
center as soon as the diagnosis is made, as recommended by
the guidelines of the International Society of Heart and
Lung Transplantation.10
Several factors could explain the apparent short-term
survival benefit observed for some patients, even though
our data do not allow us to draw any conclusions. First,
the high rate of identification of the cause of ARF (89%)
contrasts with that from the previous studies, in which a
cause was unidentified in approximately half of the cases.
One might hypothesize that this high rate of identification
has led to appropriate treatment of treatable causes. Second,
all patients with acute exacerbation of IPF or iNSIP
received steroid pulses, and most received anticoagulant
therapy. Despite the absence of blinded, controlled
studies, a benefit provided by these treatments has been
advocated.25 Third, a difference in ventilator settings (low
VT, use of a volume-driven ventilator mode [assist control])
could be involved, even if it is important to remember that
no ‘‘safe setting’’ exists.26 In particular, VT has been
substantially decreased during the last decade in patients
with reduced pulmonary compliance. In light of the proven
benefit of a low-VT approach (6 to 8 mL/kg body weight) in
acute respiratory distress syndrome, similar ventilator
settings were probably used for our patients, as evidencedardiovascular Surgery c Volume 147, Number 1 51
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weight). By contrast, VT ranged from 8 to 13 mL/kg body
weight in previous studies.2,3,27 In addition to a possible
beneficial effect of a low VT, asynchrony between
ventilator cycle and spontaneous breathing could result in
higher ventilator-induced lung injury. Asynchrony is not
likely to have occurred in our patients, however, because
the 3 experienced centers involved in this study largely
use profound sedation and neuromuscular blocking agents
in the management of such patients. Despite a low VT,
mortality was high among our patients. We hypothesize,
that despite an expected decrease in ventilator-induced
lung injury, our patients had very advanced pulmonary
fibrosis, which explains the high mortality. Furthermore,
the plateau pressure of our patients was still in a relatively
high range, with a possible superimposed deleterious
effect on the lungs.28 In addition to ventilator settings,
neuromuscular blockers, which are commonly used in all
3 centers, may also have played a role in the short-term
benefit observed in some patients,29,30 even though we
have not specifically retrieved the information concerning
the use of such agents in our patients.
Our study contains some limitations. The first is its
retrospective design. Other limitations are the relatively
low number of patients included and the long span between
the beginning and end of the patient inclusion. The
diagnosis of the cause of ARF may have been missed in
some cases because our diagnostic evaluation was not
exhaustive. For example, the search for P jirovecii was
based on direct examination of BAL fluid rather than
polymerase chain reaction, and the presence of viral
infection was not investigated. Drug toxicity was not
suspected, but obviously this diagnosis is difficult to rule
out in this setting. Our mixing of patients with IPF and
iNSIP could have introduced a bias toward improved
prognosis, even though we found no difference in prognosis
between patients with IPF and fibrosing iNSIP.CONCLUSIONS
In conclusion, our data suggest that the prognosis of
patients with IPF or fibrosing iNSIP undergoing invasive
MV for ARV, at least in the short term, may have changed
during the last decade. We found a subset of patients who
could be discharged alive from the ICU, thus providing a
potential opportunity to consider LTx in case of eligibility.
We confirm, however, that the use of invasive MV for
such patients remains associated with high mortality,
because most patients who did not undergo LTx died within
6 months. Our results are in line with the general belief that
patients do not benefit from invasive MV in this setting. On
the basis of our results, we think that initiation of invasive
MV for patients with fibrosing IPF and iNSIP should be
discussed on case-by-case basis.52 The Journal of Thoracic and Cardiovascular SurgeWe thank Jean-Damien Ricard for his helpful advice and com-
ments on the manuscript.
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